Chinese infant formula warning
This article was originally published in The Tan Sheet
Executive Summary
"Unknown safety and nutritional adequacy" of infant formula from China leads FDA to caution consumers against using such products. A formula named "Guan Wei Yuan" recently sold in an Asian retail outlet in New York was found by state agriculture officials to "contain less than [one-seventh] of the federally required minimal amount of protein per serving, approximately [one-quarter] the required amount of fat and only minute amounts of declared calcium and magnesium," FDA says. No infant formulas from China have been properly registered and shown to be produced in compliance with GMPs and quality control procedures, the agency adds...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.